Program
dupilumab
Also written as “Dupilumab”, “Dupilumab SAR231893” and “Dupilumab (SAR231893)”.
Its studies are mostly in Dermatitis, Atopic · Asthma · Eosinophilic Esophagitis · Nasal Polyps · Pulmonary Disease, Chronic Obstructive, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 529 open or running | phase 4since Jul 16, 2019 | Mar 9, 2011 | Feb 7, 2027phase 4 · NCT07905547 |
| Regeneron Pharmaceuticals | 404 open or running | phase 4since Dec 17, 2019 | Nov 10, 2009 | Apr 24, 2027phase 4 · NCT06572228 |
| Andover Eye Associates | 11 open or running | phase 2since Mar 2, 2020 | Mar 2, 2020 | none ahead |
Also a collaborator on its studies: aimmune-therapeutics-inc and statistics-data-corporation.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 43 studies since Feb 6, 2017.
- May 18, 2023Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsSanofi · NCT05878093 · 63 enrolled · China
- Jul 28, 20233 phase 1 studiesSanofi · NCT05976386, NCT05976373, NCT05976360
- Aug 1, 2023Phase 4 study in Dermatitis, AtopicSanofi · NCT05983068 · 48 enrolled · United States, United Kingdom
- Oct 19, 2023Phase 4 study in Eosinophilic EsophagitisSanofi · NCT06101095 · 69 enrolled · United States, Brazil, Canada and more
- Dec 19, 2023Phase 3 study in Respiratory SoundsSanofi · NCT06191315 · 90 planned · United States, Argentina, Brazil and more
- Feb 27, 2024Phase 3 study in Prurigo NodularisSanofi · NCT06293053 · 18 planned · United States
- Aug 23, 2024Phase 4 study in AsthmaRegeneron Pharmaceuticals · NCT06572228 · 120 enrolled · United States, Canada, Denmark and more
- Nov 12, 20242 phase 3 studies in NeurodermatitisSanofi · NCT06687980, NCT06687967
- Jun 27, 2025Phase 4 study in Pulmonary Disease, Chronic ObstructiveSanofi · NCT07053423 · 218 planned · United States, Argentina, Austria and more
- Aug 1, 2025Phase 3 study in Eosinophilic EsophagitisRegeneron Pharmaceuticals · NCT07112378 · 20 planned · United States
- Sep 15, 2025Phase 4 study in Dermatitis, AtopicRegeneron Pharmaceuticals · NCT07187089
- May 8, 2026Phase 4 study in Pulmonary Disease, Chronic ObstructiveRegeneron Pharmaceuticals · NCT07587658 · 754 planned · United States
- Jun 8, 2026Phase 1 study in Healthy VolunteersSanofi · NCT07646548 · 40 enrolled · United States
- Oct 23, 2026Phase 4 study in Dermatitis, AtopicSanofi · NCT07905547 · 56 planned
Ahead
- Feb 7, 2027Primary completion: phase 4 study in Dermatitis, AtopicSanofi · NCT07905547
- Mar 16, 2027Primary completion: phase 4 study in AsthmaSanofi · NCT05097287
- Apr 24, 2027Primary completion: phase 4 study in AsthmaRegeneron Pharmaceuticals · NCT06572228
- Apr 29, 2027Primary completion: phase 4 study in Dermatitis, AtopicSanofi · NCT05983068
TargetBeta
“Interleukin-4 receptor subunit alpha antagonist”ChEMBL 37, by rule
Other programs on IL4R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| drotokibart | Jiangsu HengRui Medicine | phase 3 | 8 |
| TQH2722 | Sino Biopharmaceutical | phase 3 | 7 |
| SHR-1819 | Jiangsu HengRui Medicine | phase 3 | 5 |
Studies
The newest 60 of 93 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07905547Dermatitis, Atopic | 4 | Not yet recruiting | Sanofi | Feb 7, 2027 | 56 |
| NCT07646548Healthy Volunteers · United States | 1 | Completed | Sanofi | Sep 30, 2026 | 40 |
| NCT07587658Pulmonary Disease, Chronic Obstructive · United States | 4 | Recruiting | Regeneron Pharmaceuticals | Jul 30, 2028 | 754 |
| NCT07187089Dermatitis, Atopic | 4 | Withdrawn | Regeneron Pharmaceuticals | Dec 23, 2027 | 0 |
| NCT07112378Eosinophilic Esophagitis · United States | 3 | Recruiting | Regeneron Pharmaceuticals | Jun 19, 2028 | 20 |
| NCT07053423Pulmonary Disease, Chronic Obstructive · United States, Argentina, Austria and more | 4 | Recruiting | Sanofi | Dec 23, 2028 | 218 |
| NCT06687980Neurodermatitis · United States, Argentina, Belgium and more | 3 | Completed | Sanofi | Jun 8, 2026 | 138 |
| NCT06687967Neurodermatitis · United States, Argentina, Canada and more | 3 | Completed | Sanofi | Jun 8, 2026 | 142 |
| NCT06572228Asthma · United States, Canada, Denmark and more | 4 | Active, not recruiting | Regeneron Pharmaceuticals | Apr 24, 2027 | 120 |
| NCT06293053Prurigo Nodularis · United States | 3 | Recruiting | Sanofi | Oct 28, 2027 | 18 |
| NCT06191315Respiratory Sounds · United States, Argentina, Brazil and more | 3 | By invitation | Sanofi | Dec 21, 2028 | 90 |
| NCT06101095Eosinophilic Esophagitis · United States, Brazil, Canada and more | 4 | Active, not recruiting | Sanofi | Nov 5, 2025 | 69 |
| NCT05983068Dermatitis, Atopic · United States, United Kingdom | 4 | Active, not recruiting | Sanofi | Apr 29, 2027 | 48 |
| NCT05976386Healthy Volunteers · United States | 1 | Completed | Sanofi | Sep 24, 2021 | 182 |
| NCT05976373Healthy Volunteers · United States | 1 | Completed | Sanofi | Mar 30, 2015 | 38 |
| NCT05976360Healthy Volunteer · United States | 1 | Completed | Sanofi | Jan 17, 2015 | 38 |
| NCT05878093Chronic Rhinosinusitis With Nasal Polyps · China | 3 | Completed | Sanofi | Sep 6, 2024 | 63 |
| NCT05831176Eosinophilic enteropathy · United States, Canada, Italy and more | 2 | Active, not recruiting | Regeneron Pharmaceuticals | Feb 23, 2026 | 22 |
| NCT05731128Colitis, Ulcerative · United States, Argentina, Canada and more | 2 | Active, not recruiting | Sanofi | May 13, 2026 | 68 |
| NCT05680298Dermatitis, Atopic · China | 4 | Completed | Sanofi | Dec 22, 2023 | 34 |
| NCT05624112Dermatitis, Atopic · China | 4 | Completed | Sanofi | Jan 25, 2024 | 44 |
| NCT05590585Dermatitis, Atopic · United States | 4 | Completed | Regeneron Pharmaceuticals | Nov 14, 2024 | 124 |
| NCT05526521Chronic Urticaria · United States, Canada, Japan | 3 | Completed | Sanofi | Nov 11, 2024 | 15 |
| NCT05263206Pruritus · United States, Argentina, Canada and more | 3 | Recruiting | Sanofi | Jun 2, 2027 | 284 |
| NCT05097287Asthma · United States, Belgium, Brazil and more | 4 | Active, not recruiting | Sanofi | Mar 16, 2027 | 1,339 |
| NCT05049122Chronic Rhinosinusitis With Nasal Polyps · Japan | 4 | Completed | Sanofi | Dec 21, 2022 | 25 |
| NCT04998604Asthma · United States, Belgium, Canada and more | 4 | Completed | Sanofi | Oct 16, 2024 | 360 |
| NCT04823130Dermatitis, Atopic · United States, Germany | 4 | Completed | Sanofi | Jun 30, 2022 | 54 |
| NCT04718870Dermatitis, Atopic · United States, United Kingdom | 4 | Completed | Sanofi | Sep 7, 2022 | 41 |
| NCT04684524Allergic Fungal Sinusitis · United States, Argentina, Canada and more | 3 | Completed | Sanofi | Dec 14, 2024 | 62 |
| NCT04681729Cold Urticaria · United States, Argentina, Canada and more | 3 | Completed | Sanofi | Feb 2, 2023 | 82 |
| NCT04678882Dermatitis, Atopic · Japan | 3 | Completed | Sanofi | Dec 14, 2021 | 62 |
| NCT04678856Sinusitis · United States, Argentina, Belgium and more | 2 | Completed | Sanofi | Nov 14, 2023 | 71 |
| NCT04502862Asthma · United States, Argentina, Canada and more | 4 | Completed | Sanofi | Oct 3, 2023 | 202 |
| NCT04456673Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Feb 28, 2024 | 935 |
| NCT04447417Dermatitis, Atopic · United States, Canada | 4 | Completed | Sanofi | Jun 17, 2021 | 52 |
| NCT04442269Aspergillosis, Allergic Bronchopulmonary · United States, Bulgaria, France and more | 2 | Completed | Regeneron Pharmaceuticals | Jul 27, 2023 | 62 |
| NCT04417894Moderate to Severe Atopic Hand and Foot Dermatitis · United States, Germany, Japan and more | 3 | Completed | Regeneron Pharmaceuticals | Aug 31, 2022 | 133 |
| NCT04400318Asthma · United States, Bulgaria, Denmark and more | 4 | Completed | Sanofi | Jun 26, 2023 | 109 |
| NCT04394351Eosinophilic Esophagitis · United States, Canada | 3 | Completed | Regeneron Pharmaceuticals | Jun 2, 2022 | 102 |
| NCT04296864Atopic Keratoconjunctivitis · United States | 2 | Recruiting | Andover Eye Associates | Jan 2025 | 42 |
| NCT04206553Pemphigoid, Bullous · United States, Australia, France and more | 3 | Completed | Regeneron Pharmaceuticals | Jul 12, 2024 | 106 |
| NCT04203797Asthma · United States, France, Germany and more | 4 | Completed | Regeneron Pharmaceuticals | Jul 15, 2023 | 40 |
| NCT04202679Neurodermatitis · United States, Canada, Chile and more | 3 | Completed | Sanofi | Aug 30, 2021 | 160 |
| NCT04183335Neurodermatitis · United States, Argentina, China and more | 3 | Completed | Sanofi | Nov 12, 2021 | 151 |
| NCT04180488Chronic Urticaria · United States, Argentina, Canada and more | 3 | Completed | Sanofi | Aug 1, 2024 | 397 |
| NCT04033367Dermatitis, Atopic · United States, Australia, France and more | 4 | Completed | Sanofi | Oct 6, 2021 | 188 |
| NCT03930732Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more | 3 | Completed | Sanofi | Feb 8, 2023 | 939 |
| NCT03793608Peanut Hypersensitivity · United States, Canada | 2 | Completed | Regeneron Pharmaceuticals | Feb 19, 2021 | 25 |
| NCT03912259Dermatitis, Atopic · China | 3 | Completed | Sanofi | Feb 14, 2020 | 165 |
| NCT03782532Asthma · China, India | 3 | Completed | Sanofi | May 21, 2022 | 486 |
| NCT03736967Dermatitis, Atopic · United States, Belgium, Czechia and more | 2 | Terminated | Regeneron Pharmaceuticals | Mar 13, 2020 | 206 |
| NCT03682770Peanut Hypersensitivity · United States | 2 | Completed | Regeneron Pharmaceuticals | Oct 16, 2020 | 148 |
| NCT03633617Eosinophilic Esophagitis · United States, Australia, Belgium and more | 3 | Completed | Regeneron Pharmaceuticals | Sep 9, 2021 | 321 |
| NCT03620747Asthma · United States, Argentina, Belgium and more | 3 | Completed | Sanofi | Feb 18, 2022 | 393 |
| NCT03558997Rhinitis, Allergic · United States, Canada | 2 | Completed | Regeneron Pharmaceuticals | May 14, 2019 | 103 |
| NCT03560466Asthma · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Apr 1, 2025 | 378 |
| NCT03345914Dermatitis, Atopic · United States, Canada, Czechia and more | 3 | Completed | Regeneron Pharmaceuticals | Jun 20, 2019 | 367 |
| NCT03112577Asthma · United States, United Kingdom | 1 | Completed | Regeneron Pharmaceuticals | Mar 20, 2019 | 32 |
| NCT03346434Dermatitis, Atopic · United States, Germany, Poland and more | 3 | Completed | Regeneron Pharmaceuticals | Jul 8, 2021 | 202 |
How it is read
Names in the registry
- “Dupilumab”, 55 entries
- “Dupilumab SAR231893”, 13 entries
- “dupilumab”, 10 entries
- “Dupilumab (SAR231893)”, 5 entries
- “REGN668”, 4 entries
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 32 studies
- Asthma, 17 studies
- Eosinophilic Esophagitis, 5 studies
- Nasal Polyps, 5 studies
- Pulmonary Disease, Chronic Obstructive, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.